FVCBankcorp Q2 net income rises on higher loan yields, lower costs
Reuters2026/07/21 20:11
Overview
U.S. community bank's Q2 net income rose 45% year-over-year, driven by higher loan yields
Diluted EPS for Q2 rose 45% to $0.45 from $0.31 a year ago
Q2 results include one-time gain from sale of insurance group stake
Outlook
Company anticipates continued improvement in loan yields due to scheduled loan repricings
FVCBankcorp expects efforts to attain appropriate yields on new originations to support loan yield growth
Company remains focused on expanding customer base and operating efficiency
Result Drivers
HIGHER LOAN YIELDS - Co said increased loan yields and higher average loan balances drove net interest income and margin expansion
LOWER DEPOSIT COSTS - Co attributed margin improvement to lower deposit costs and repricing of funding sources
ONE-TIME GAIN - Q2 results included a one-time pre-tax gain from sale of insurance group stake
Company press release: ID:nBw9c7XXXa
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q2 EPS |
|
$0.45 |
$0.36 (2 Analysts) |
Q2 Net Income |
|
$8.22 mln |
|
Q2 Net Interest Income |
|
$19.15 mln |
|
Q2 Net Interest Margin |
|
3.53% |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the banks peer group is "buy"
Wall Street's median 12-month price target for FVCBankcorp Inc is $18.38, about 4.8% above its July 20 closing price of $17.54
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 10 three months ago
Reuters Recommended Reads
July 20 - ServisFirst Bancshares Q2 EPS rises 40% on loan growth, higher net interest margin
July 21 - KeyCorp Q2 net interest income rises on lower deposit costs
July 21 - Southern First Bancshares' Q2 profit rises on loan growth and margin expansion
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BioMarin files Form 3 for director Robert M. Plenge, reporting no beneficial ownership
Bioceres Crop Solutions 4Q Rev $55.9M >BIOX
Red Robin files Form 3 beneficial ownership statement for CMO Scott Hudler
Telix Pharmaceuticals Target Price Raised 2.4% to A$30.00/Share by Jefferies>TLX.AU